Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2025; 21
DOI: 10.1055/s-0045-1807779
BREAST TUMORS
2090
POSTER PRESENTATION

Metastasis de novo (MTDN) is associated with poor progression-free survival (PFS) in HR+/HER2- breast cancer treated with CDK4/6 inhibitors (ICDK4/6) in first line (1L)

Authors

  • Lucas de Amorim Gouvea

  • Elizabeth Santana dos Santos

  • Vladmir Cláudio Cordeiro de Lima

  • Solange Moraes Sanches

  • Marcelle Goldner Cesca

  • Nathalia Machado Soldi

  • Viviane Primo Basilio de Souza

  • Amanda Alencar Cavalcanti Carneiro da Cunha

  • Victor Gabriel Bertoli

  • Eduardda Beatryz Silva

Further Information
  All articles of this category

Keywords

luminal breast cancer - CDK4/6 inhibitors - metastasis - metastasis de novo


Publication History

Article published online:
06 May 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Lucas de Amorim Gouvea, Elizabeth Santana dos Santos, Vladmir Cláudio Cordeiro de Lima, Solange Moraes Sanches, Marcelle Goldner Cesca, Nathalia Machado Soldi, Viviane Primo Basilio de Souza, Amanda Alencar Cavalcanti Carneiro da Cunha, Victor Gabriel Bertoli, Eduardda Beatryz Silva. Metastasis de novo (MTDN) is associated with poor progression-free survival (PFS) in HR+/HER2- breast cancer treated with CDK4/6 inhibitors (ICDK4/6) in first line (1L). Brazilian Journal of Oncology 2025; 21.
DOI: 10.1055/s-0045-1807779